💨 Abstract

Xeris Biopharma Holdings, Inc. (XERS) reported a Q1 2025 loss of $9.2 million (6 cents per share), surpassing analysts' expectations of a 7 cents per share loss. Revenue was $60.1 million, also exceeding forecasts of $57.4 million. The company anticipates full-year revenue between $260 million and $275 million.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖